← Dow overview

Dow vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dow Inc (DOW)

Q3 2026
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

August 2026
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Latest
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Q2 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

June 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

Chemours Co (CC)

Q3 2026
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 2026
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest
▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

  • EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.

    This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.

  • New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.

    It introduces a new legal threat that could increase costs and uncertainty for CC.

  • 2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.

    It provides a forward-looking financial picture that directly influences CC's valuation.

  • Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.

    It finalizes a major liability that affects CC's financial obligations and investor sentiment.

© 2026 MarketDXWhy